Equities Analysts Offer Predictions for GALT FY2027 Earnings

Galectin Therapeutics Inc. (NASDAQ:GALT) – Analysts at HC Wainwright dropped their FY2027 earnings per share estimates for Galectin Therapeutics in a research note issued to investors on Friday, November 15th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of $1.25 for the year, down from their prior estimate of $1.29. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2028 earnings at $3.39 EPS.

Separately, StockNews.com lowered shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th.

Galectin Therapeutics Stock Down 2.9 %

GALT opened at $2.69 on Monday. The company has a market cap of $167.53 million, a P/E ratio of -3.68 and a beta of 0.62. The firm’s 50-day moving average price is $2.69 and its 200-day moving average price is $2.61. Galectin Therapeutics has a 52-week low of $1.55 and a 52-week high of $4.27.

Institutional Trading of Galectin Therapeutics

Several large investors have recently added to or reduced their stakes in GALT. Vanguard Group Inc. lifted its holdings in shares of Galectin Therapeutics by 2.0% during the first quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock worth $4,732,000 after purchasing an additional 38,037 shares during the period. Traynor Capital Management Inc. raised its position in Galectin Therapeutics by 23.5% during the 2nd quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock worth $97,000 after buying an additional 8,164 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Galectin Therapeutics during the 2nd quarter valued at approximately $146,000. Commonwealth Equity Services LLC lifted its stake in Galectin Therapeutics by 317.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock valued at $1,092,000 after acquiring an additional 367,610 shares during the period. Finally, Rhumbline Advisers purchased a new stake in shares of Galectin Therapeutics in the 2nd quarter valued at $44,000. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.